These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

168 related items for PubMed ID: 23627188

  • 1. Complement factor H functional assay may help to monitor atypical haemolytic uraemic syndrome: a pilot study.
    Massart A, Golmarvi S, Hachimi-Idrissi S, Broeders E, Tournay Y, Nortier J, Abramowicz D, Tielemans C, Stordeur P.
    Acta Clin Belg; 2013; 68(1):9-14. PubMed ID: 23627188
    [Abstract] [Full Text] [Related]

  • 2. An ELISA assay with two monoclonal antibodies allows the estimation of free factor H and identifies patients with acquired deficiency of this complement regulator.
    Nozal P, Garrido S, Alba-Domínguez M, Espinosa L, Peña A, Córdoba SR, Sánchez-Corral P, López-Trascasa M.
    Mol Immunol; 2014 Apr; 58(2):194-200. PubMed ID: 24378252
    [Abstract] [Full Text] [Related]

  • 3. [Atypical hemolytic-uremic syndrome related to abnormalities within the complement system].
    Frémeaux-Bacchi V, Fakhouri F, Roumenina L, Dragon-Durey MA, Loirat C.
    Rev Med Interne; 2011 Apr; 32(4):232-40. PubMed ID: 21376430
    [Abstract] [Full Text] [Related]

  • 4. Complement activation patterns in atypical haemolytic uraemic syndrome during acute phase and in remission.
    Volokhina EB, Westra D, van der Velden TJ, van de Kar NC, Mollnes TE, van den Heuvel LP.
    Clin Exp Immunol; 2015 Aug; 181(2):306-13. PubMed ID: 25079699
    [Abstract] [Full Text] [Related]

  • 5. A novel quantitative hemolytic assay coupled with restriction fragment length polymorphisms analysis enabled early diagnosis of atypical hemolytic uremic syndrome and identified unique predisposing mutations in Japan.
    Yoshida Y, Miyata T, Matsumoto M, Shirotani-Ikejima H, Uchida Y, Ohyama Y, Kokubo T, Fujimura Y.
    PLoS One; 2015 Aug; 10(5):e0124655. PubMed ID: 25951460
    [Abstract] [Full Text] [Related]

  • 6. Molecular basis and outcomes of atypical haemolytic uraemic syndrome in Czech children.
    Štolbová Š, Bezdíčka M, Seeman T, Prohászka Z, Csuka D, Hrachovinová I, Burkert J, Šimánková N, Průhová Š, Zieg J.
    Eur J Pediatr; 2020 Nov; 179(11):1739-1750. PubMed ID: 32424742
    [Abstract] [Full Text] [Related]

  • 7. Haemolytic uraemic syndrome caused by factor H mutation: is single kidney transplantation under intensive plasmatherapy an option?
    Hirt-Minkowski P, Schaub S, Mayr M, Schifferli JA, Dickenmann M, Frémeaux-Bacchi V, Steiger J.
    Nephrol Dial Transplant; 2009 Nov; 24(11):3548-51. PubMed ID: 19633317
    [Abstract] [Full Text] [Related]

  • 8. Functional analyses indicate a pathogenic role of factor H autoantibodies in atypical haemolytic uraemic syndrome.
    Strobel S, Hoyer PF, Mache CJ, Sulyok E, Liu WS, Richter H, Oppermann M, Zipfel PF, Józsi M.
    Nephrol Dial Transplant; 2010 Jan; 25(1):136-44. PubMed ID: 19666655
    [Abstract] [Full Text] [Related]

  • 9. Complement therapy in atypical haemolytic uraemic syndrome (aHUS).
    Wong EK, Goodship TH, Kavanagh D.
    Mol Immunol; 2013 Dec 15; 56(3):199-212. PubMed ID: 23810412
    [Abstract] [Full Text] [Related]

  • 10. Successful plasma therapy for atypical hemolytic uremic syndrome caused by factor H deficiency owing to a novel mutation in the complement cofactor protein domain 15.
    Licht C, Weyersberg A, Heinen S, Stapenhorst L, Devenge J, Beck B, Waldherr R, Kirschfink M, Zipfel PF, Hoppe B.
    Am J Kidney Dis; 2005 Feb 15; 45(2):415-21. PubMed ID: 15685522
    [Abstract] [Full Text] [Related]

  • 11. Complement Genetic Variants and FH Desialylation in S. pneumoniae-Haemolytic Uraemic Syndrome.
    Gómez Delgado I, Corvillo F, Nozal P, Arjona E, Madrid Á, Melgosa M, Bravo J, Szilágyi Á, Csuka D, Veszeli N, Prohászka Z, Sánchez-Corral P.
    Front Immunol; 2021 Feb 15; 12():641656. PubMed ID: 33777036
    [Abstract] [Full Text] [Related]

  • 12. An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document.
    Campistol JM, Arias M, Ariceta G, Blasco M, Espinosa L, Espinosa M, Grinyó JM, Macía M, Mendizábal S, Praga M, Román E, Torra R, Valdés F, Vilalta R, Rodríguez de Córdoba S.
    Nefrologia; 2015 Feb 15; 35(5):421-47. PubMed ID: 26456110
    [Abstract] [Full Text] [Related]

  • 13. Plasma therapy for atypical haemolytic uraemic syndrome associated with heterozygous factor H mutations.
    Kim JJ, Goodship TH, Tizard J, Inward C.
    Pediatr Nephrol; 2011 Nov 15; 26(11):2073-6. PubMed ID: 21717289
    [Abstract] [Full Text] [Related]

  • 14. Atypical haemolytic uraemic syndrome.
    Kavanagh D, Goodship TH, Richards A.
    Br Med Bull; 2006 Nov 15; 77-78():5-22. PubMed ID: 16968692
    [Abstract] [Full Text] [Related]

  • 15. Functional evaluation of factor H genetic and acquired abnormalities: application for atypical hemolytic uremic syndrome (aHUS).
    Roumenina LT, Roquigny R, Blanc C, Poulain N, Ngo S, Dragon-Durey MA, Frémeaux-Bacchi V.
    Methods Mol Biol; 2014 Nov 15; 1100():237-47. PubMed ID: 24218264
    [Abstract] [Full Text] [Related]

  • 16. Adverse outcomes in obstetric-atypical haemolytic uraemic syndrome: a case series analysis.
    Kozlovskaya NL, Korotchaeva YV, Bobrova LA.
    J Matern Fetal Neonatal Med; 2019 Sep 15; 32(17):2853-2859. PubMed ID: 29606012
    [Abstract] [Full Text] [Related]

  • 17. Haemolytic uraemic syndrome and mutations of the factor H gene: a registry-based study of German speaking countries.
    Neumann HP, Salzmann M, Bohnert-Iwan B, Mannuelian T, Skerka C, Lenk D, Bender BU, Cybulla M, Riegler P, Königsrainer A, Neyer U, Bock A, Widmer U, Male DA, Franke G, Zipfel PF.
    J Med Genet; 2003 Sep 15; 40(9):676-81. PubMed ID: 12960213
    [Abstract] [Full Text] [Related]

  • 18. Cryptic activity of atypical hemolytic uremic syndrome and eculizumab treatment.
    Belingheri M, Possenti I, Tel F, Paglialonga F, Testa S, Salardi S, Ardissino G.
    Pediatrics; 2014 Jun 15; 133(6):e1769-71. PubMed ID: 24843058
    [Abstract] [Full Text] [Related]

  • 19. Autoantibodies to CD59, CD55, CD46 or CD35 are not associated with atypical haemolytic uraemic syndrome (aHUS).
    Watson R, Wearmouth E, McLoughlin AC, Jackson A, Ward S, Bertram P, Bennaceur K, Barker CE, Pappworth IY, Kavanagh D, Lea SM, Atkinson JP, Goodship TH, Marchbank KJ.
    Mol Immunol; 2015 Feb 15; 63(2):287-96. PubMed ID: 25150608
    [Abstract] [Full Text] [Related]

  • 20. Ocular involvement in atypical haemolytic uraemic syndrome.
    Sampedro López A, Domínguez Moro B, Baltar Martin JM, Garcia Monteavaro C, Barbón García JJ.
    Arch Soc Esp Oftalmol; 2017 Dec 15; 92(12):594-597. PubMed ID: 28347544
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.